SCHEMBL1521500

SCHEMBL1521500

CNc1ncc2c(n1)N(C(C)C)C(=O)N(c1cc(NC(=O)Nc3cc(C(C)(C)C)on3)c(F)cc1C)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
BRAF P15056 4/20 0.39
CSF1R P07333 1/20 0.39
MAPK14 Q16539 5/20 0.39
RAF1 P04049 5/20 0.37
MAPK13 O15264 2/20 0.37
MAPK3 P27361 2/20 0.37
FLT3 P36888 3/20 0.37
ABL1 P00519 2/20 0.36
KRAS P01116 1/20 0.36
FYN P06241 1/20 0.36
ARAF P10398 1/20 0.36
SRC P12931 1/20 0.36
EPHA2 P29317 1/20 0.36
KDR P35968 1/20 0.36
CSK P41240 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
IRAK1 P51617 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521517 0.90 ABL1 (0.44) RAB9ANPC1MAPK14ABL1SRC
SCHEMBL1521598 0.90 BRAF (0.42) BRAFMAPK14RAF1MAPK13ABL1
SCHEMBL1521923 0.88 RAB9A (0.43) RAB9ANPC1BRAFCSF1RMAPK14
SCHEMBL1521748 0.88 RAB9A (0.43) RAB9ANPC1BRAFCSF1RMAPK14
SCHEMBL1522022 0.83 ABL1 (0.39) BRAFMAPK14RAF1MAPK13ABL1
SCHEMBL1521888 0.81 RAB9A (0.45) RAB9ANPC1BRAFCSF1RMAPK14
SCHEMBL1521733 0.81 ABL1 (0.45) BRAFRAF1MAPK3ABL1KRAS
SCHEMBL1521858 0.79 BRAF (0.46) BRAFMAPK14RAF1MAPK13ABL1
SCHEMBL4273911 0.79 RAB9A (0.43) RAB9ANPC1BRAFCSF1RMAPK14
SCHEMBL1522013 0.79 ABL1 (0.43) ABL1SRCKDREPHB4RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 RAB9A 1244/4885NPC1 4287/4885BRAF 1/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 RAB9A 1244/4885NPC1 4287/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.